PMID- 32823914 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201030 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 10 IP - 3 DP - 2020 Aug 14 TI - Resting-State Isolated Effective Connectivity of the Cingulate Cortex as a Neurophysiological Biomarker in Patients with Severe Treatment-Resistant Schizophrenia. LID - 10.3390/jpm10030089 [doi] LID - 89 AB - Background: The neural basis of treatment-resistant schizophrenia (TRS) remains unclear. Previous neuroimaging studies suggest that aberrant connectivity between the anterior cingulate cortex (ACC) and default mode network (DMN) may play a key role in the pathophysiology of TRS. Thus, we aimed to examine the connectivity between the ACC and posterior cingulate cortex (PCC), a hub of the DMN, computing isolated effective coherence (iCoh), which represents causal effective connectivity. Methods: Resting-state electroencephalogram with 19 channels was acquired from seventeen patients with TRS and thirty patients with non-TRS (nTRS). The iCoh values between the PCC and ACC were calculated using sLORETA software. We conducted four-way analyses of variance (ANOVAs) for iCoh values with group as a between-subject factor and frequency, directionality, and laterality as within-subject factors and post-hoc independent t-tests. Results: The ANOVA and post-hoc t-tests for the iCoh ratio of directionality from PCC to ACC showed significant findings in delta (t(45) = 7.659, p = 0.008) and theta (t(45) = 8.066, p = 0.007) bands in the left side (TRS < nTRS). Conclusion: Left delta and theta PCC and ACC iCoh ratio may represent a neurophysiological basis of TRS. Given the preliminary nature of this study, these results warrant further study to confirm the importance of iCoh as a clinical indicator for treatment-resistance. FAU - Wada, Masataka AU - Wada M AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Nakajima, Shinichiro AU - Nakajima S AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Tarumi, Ryosuke AU - Tarumi R AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan. AD - Department of Psychiatry, Komagino Hospital, Tokyo 193-8505, Japan. FAU - Masuda, Fumi AU - Masuda F AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Miyazaki, Takahiro AU - Miyazaki T AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Tsugawa, Sakiko AU - Tsugawa S AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Ogyu, Kamiyu AU - Ogyu K AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Honda, Shiori AU - Honda S AD - Graduate School of Media and Governance, Keio University, Kanagawa, Tokyo 252-0882, Japan. FAU - Matsushita, Karin AU - Matsushita K AD - Faculty of Environment and Information Studies, Keio University, Kanagawa, Tokyo 252-0882, Japan. FAU - Kikuchi, Yudai AU - Kikuchi Y AD - Faculty of Environment and Information Studies, Keio University, Kanagawa, Tokyo 252-0882, Japan. FAU - Fujii, Shinya AU - Fujii S AD - Faculty of Environment and Information Studies, Keio University, Kanagawa, Tokyo 252-0882, Japan. FAU - Blumberger, Daniel M AU - Blumberger DM AD - Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON M6J 1H4, Canada. FAU - Daskalakis, Zafiris J AU - Daskalakis ZJ AD - Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON M6J 1H4, Canada. FAU - Mimura, Masaru AU - Mimura M AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Noda, Yoshihiro AU - Noda Y AUID- ORCID: 0000-0002-2155-0357 AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan. LA - eng GR - 20807226/Japan Agency for Medical Research and Development/ GR - 20807226/Japan Society for the Promotion of Science/ PT - Journal Article DEP - 20200814 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC7564631 OTO - NOTNLM OT - anterior cingulate cortex OT - causal effective connectivity OT - default mode network OT - isolated effective coherence OT - posterior cingulate cortex OT - resting-state electroencephalography OT - treatment-resistant schizophrenia COIS- M.W., R.T., F.M., T.M., S.T., K.O., S.H., K.M., and Y.K. report no biomedical interests. S.N. has received fellowship grants from CIHR, Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Takeda Science Foundation, Uehara Memorial Foundation, and Daiichi Sankyo Scholarship Donation Program within the past three years. S.N. has also received research supports, manuscript fees, or speaker's honoraria from Dainippon Sumitomo Pharma, Meiji-Seika Pharma, Otsuka Pharmaceutical, Shionogi, and Yoshitomi Yakuhin within the past three years. Z.J.D. has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc and Magventure Inc. His work was supported by the Ontario Mental Health Foundation (OMHF), the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMH), and the Temerty Family and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. M.M. has received research support from Japan Society for the Promotion of Science and grants or speaker's honoraria from Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Mochida Pharmaceutical, M.S.D., Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin within the past three years. D.M.B. receives research support from the Canadian Institutes of Health Research (CIHR), National Institutes of Health-US (NIH), Weston Brain Institute, Brain Canada, and the Temerty Family through the CAMH Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he is the site principal investigator for three sponsor-initiated studies for Brainsway Ltd. He received in-kind equipment support from Magventure for an investigator-initiated study. He received medication supplies for an investigator-initiated trial from Indivior. He has participated in an advisory board for Janssen. Y.N. has received a Grant-in-Aid for Young Scientists (KAKENHI), a research grant from Japan Agency for Medical Research and development (AMED), an investigator-initiated clinical study grant from TEIJIN PHARMA LIMITED. Y.N. also received research grants from Japan Health Foundation, Meiji Yasuda Mental Health Foundation, Mitsui Life Social Welfare Foundation, Takeda Science Foundation, SENSHIN Medical Research Foundation, Health Science Center Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research, and Daiichi Sankyo Scholarship Donation Program. He has received research supports from Otsuka Pharmaceutical, Shionogi, and Meiji Seika Pharma. Y.N. also received equipment-in-kind supports for an investigator-initiated study from Magventure Inc., Inter Reha Co., Ltd., Rogue Resolutions Ltd., and Miyuki Giken Co., Ltd. EDAT- 2020/08/23 06:00 MHDA- 2020/08/23 06:01 PMCR- 2020/09/01 CRDT- 2020/08/23 06:00 PHST- 2020/06/21 00:00 [received] PHST- 2020/08/09 00:00 [revised] PHST- 2020/08/12 00:00 [accepted] PHST- 2020/08/23 06:00 [entrez] PHST- 2020/08/23 06:00 [pubmed] PHST- 2020/08/23 06:01 [medline] PHST- 2020/09/01 00:00 [pmc-release] AID - jpm10030089 [pii] AID - jpm-10-00089 [pii] AID - 10.3390/jpm10030089 [doi] PST - epublish SO - J Pers Med. 2020 Aug 14;10(3):89. doi: 10.3390/jpm10030089.